A Phase 2 Study of Pyrotinib in Patients With Non-Small Cell Lung Cancer (NSCLC), With at Least One Prior Systemic Treatment, Locally Advanced or Metastatic, With EGFR or ERBB2 Exon 20 Insertion Mutation (PEER20)
Latest Information Update: 08 Oct 2021
At a glance
- Drugs Pyrotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms PEER20
Most Recent Events
- 12 Sep 2019 New trial record